331 related articles for article (PubMed ID: 3932908)
1. Response of ovarian cancer to combined cytotoxic agents in the subrenal capsule assay: Part I.
Mäenpää J; Kangas L; Grönroos M
Obstet Gynecol; 1985 Nov; 66(5):708-13. PubMed ID: 3932908
[TBL] [Abstract][Full Text] [Related]
2. Subrenal capsule assay as a predictor of clinical response of ovarian cancer to chemotherapy: Part II.
Mäenpää J
Obstet Gynecol; 1985 Nov; 66(5):714-8. PubMed ID: 3903584
[TBL] [Abstract][Full Text] [Related]
3. Subrenal capsule assay in choosing cytostatics for gynaecological tumours.
Mäenpää J; Grönroos M; Kangas L
Ann Chir Gynaecol Suppl; 1985; 199():28-30. PubMed ID: 3864390
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinoma.
Barlow JJ; Lele SB
Cancer Treat Rep; 1984 Dec; 68(12):1433-8. PubMed ID: 6439408
[TBL] [Abstract][Full Text] [Related]
5. Ultrastructural effects of alpha and gamma interferons and cytostatics on ovarian cancer cells in the subrenal capsule assay (SRCA).
Söderström KO; Mäenpää J; Cantell K; Kangas L; Grönroos M
Ann Chir Gynaecol Suppl; 1985; 199():38-43. PubMed ID: 3933399
[TBL] [Abstract][Full Text] [Related]
6. Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU; CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.
Pasmantier MW; Coleman M; Silver RT; Ballard WP
Cancer Treat Rep; 1985 Jun; 69(6):689-93. PubMed ID: 3926310
[TBL] [Abstract][Full Text] [Related]
7. [Clinical application of subrenal capsule assay in ovarian cancer].
Maeda K; Ushijima H; Shimamoto T; Shigematsu T; Kurano A; Watanabe Y; Jimi S; Okadome M; Mashiba H
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Dec; 41(12):1896-902. PubMed ID: 2592813
[TBL] [Abstract][Full Text] [Related]
8. Antitumour effect of interferons, cytostatic drugs and their combinations in subrenal capsule assay (SRCA).
Kangas L; Cantell K; Grönroos M; Mäenpää J; Perilä M
Ann Chir Gynaecol Suppl; 1985; 199():60-3. PubMed ID: 2415035
[TBL] [Abstract][Full Text] [Related]
9. The subrenal capsule assay in selecting chemotherapy for ovarian cancer: a prospective randomized trial.
Mäenpää JU; Heinonen E; Hinkka SM; Karnani P; Klemi PJ; Korpijaakko TA; Kuoppala TA; Laine AM; Lähde MA; Nuoranne EK
Gynecol Oncol; 1995 Jun; 57(3):294-8. PubMed ID: 7774832
[TBL] [Abstract][Full Text] [Related]
10. Combination chemotherapy tested in a short-term thymidine incorporation assay in primary cultures of ovarian adenocarcinomas.
Hayward IP; Hurst T; Parsons PG; Khoo SK
Int J Cell Cloning; 1992 May; 10(3):182-9. PubMed ID: 1613269
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide.
Ohie S; Udagawa Y; Kozu A; Komuro Y; Aoki D; Nozawa S; Moossa AR; Hoffman RM
Anticancer Res; 2000; 20(3B):2049-54. PubMed ID: 10928150
[TBL] [Abstract][Full Text] [Related]
12. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
13. [Results of the first Austrian multicenter ovarian cancer study: prospective randomized comparison of sequential chemotherapy (adriamycin/cisplatin--vincristine/cyclophosphamide--methotrexate) with 2 standard protocols (adriamycin/cyclophosphamide or adriamycin/cisplatin) in stage III and IV patients].
Salzer H; Gitsch E; Dittrich C; Sevelda P; Karrer K; Schemper M; Stempel-Smekal G; Langer M; Wagner G; Rainer H
Geburtshilfe Frauenheilkd; 1985 Nov; 45(11):761-8. PubMed ID: 3908214
[TBL] [Abstract][Full Text] [Related]
14. Hexamethylmelamine-CAF (cyclophosphamide, methotrexate, and 5-FU) and cisplatin-CAF in refractory ovarian cancer.
Sessa C; D'Incalci M; Valente I; Bolis G; Colombo N; Mangioni C
Cancer Treat Rep; 1982 May; 66(5):1233-4. PubMed ID: 6805951
[No Abstract] [Full Text] [Related]
15. [Chemotherapy of epithelial ovarian carcinoma].
Bruntsch U; Gallmeier WM
MMW Munch Med Wochenschr; 1983 Nov; 125(44):993-5. PubMed ID: 6417517
[No Abstract] [Full Text] [Related]
16. Acquisition of multidrug resistance in recurrent breast cancer demonstrated by the histoculture drug response assay.
Tanino H; Oura S; Hoffman RM; Kubota T; Furukawa T; Arimoto J; Yoshimasu T; Hirai I; Bessho T; Suzuma T; Sakurai T; Naito Y
Anticancer Res; 2001; 21(6A):4083-6. PubMed ID: 11911296
[TBL] [Abstract][Full Text] [Related]
17. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.
Elliott WL; Roberts BJ; Howard CT; Leopold WR
Cancer Res; 1994 Aug; 54(16):4412-8. PubMed ID: 8044790
[TBL] [Abstract][Full Text] [Related]
19. [Combination chemotherapy of ovarian cancer with cisplatinum, aclarubicin and tegafur].
Wada Y; Suzuki M; Shinagawa S; Saito Y; Nishiya I; Maki M; Yajima A; Hiroi M; Sato A
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2589-94. PubMed ID: 2505683
[TBL] [Abstract][Full Text] [Related]
20. Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer.
Eltabbakh GH; Piver MS; Hempling RE; Recio FO; Lele SB; Marchetti DL; Baker TR; Blumenson LE
Gynecol Oncol; 1998 Sep; 70(3):392-7. PubMed ID: 9790793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
